APP and Alzheimer disease: In Wang’s study, EA at GV20 for 4 weeks suppressed astrocytosis in APP mice, ameliorated AD-induced cognitive impairment and memory decline, and attenuated the upregulation of glial fibrillary acidic protein (GFAP) in reactive astrocytes, implying the therapeutic pathway of EA via astrocytic alteration (Wang et al., 2014).